LXG.H — Lexagene Holdings Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | 49.31% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -446.53% | ||
| Return on Equity | -326.07% | ||
| Operating Margin | -7760.89% | ||
Financial Summary
| Year End 28th Feb | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.06 | 0.08 | 3.53 | 7.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +49.31 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.
Directors
- John Regan CHM
- Jeffrey Mitchell CFO
- Steven Armstrong COO
- Eleanor Kolossovski DMK
- Joseph Caruso IND (58)
- Stephen Mastrocola IND
- Tom Slezak IND
- Jane Sykes IND
- Last Annual
- February 28th, 2022
- Last Interim
- November 30th, 2022
- Incorporated
- April 26th, 2007
- Public Since
- August 28th, 2007
- No. of Employees
- 33
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 140,740,255
- Address
- 500 CUMMINGS CTR., SUITE 4550, BEVERLY, 01915
- Web
- https://lexagene.com/
- Phone
- +1 6046810084
- Auditors
- RSM US LLP
Upcoming Events for LXG.H
Similar to LXG.H
Advanced Proteome Therapeutics
TSX Venture Exchange
Claritas Pharmaceuticals
TSX Venture Exchange
CVR Medical
TSX Venture Exchange
Many Bright Ideas Technologies
TSX Venture Exchange
FAQ
As of Today at 01:14 UTC, shares in Lexagene Holdings are trading at . This share price information is delayed by 15 minutes.
Shares in Lexagene Holdings last closed at and the price had moved by -63.79% over the past 365 days. In terms of relative price strength the Lexagene Holdings share price has underperformed the Toronto Stock Exchange 300 Composite Index by -66.57% over the past year.
The overall consensus recommendation for Lexagene Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLexagene Holdings does not currently pay a dividend.
Lexagene Holdings does not currently pay a dividend.
Lexagene Holdings does not currently pay a dividend.
To buy shares in Lexagene Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of , shares in Lexagene Holdings had a market capitalisation of .
Here are the trading details for Lexagene Holdings:
- Country of listing: Canada
- Exchange: NEX
- Ticker Symbol: LXG.H
Based on an overall assessment of its quality, value and momentum Lexagene Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lexagene Holdings. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -33.85%.
As of the last closing price of , shares in Lexagene Holdings were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lexagene Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lexagene Holdings' management team is headed by:
- John Regan - CHM
- Jeffrey Mitchell - CFO
- Steven Armstrong - COO
- Eleanor Kolossovski - DMK
- Joseph Caruso - IND
- Stephen Mastrocola - IND
- Tom Slezak - IND
- Jane Sykes - IND